A real-world cohort study finds that denosumab use is linked to a lower risk for incident knee osteoarthritis in adults with osteoporosis than the use of bisphosphonates.
On Dec 19, 2025, the US Food and Drug Administration (FDA) announced a major milestone by qualifying total hip bone mineral density (BMD), assessed by dual-energy X-ray absorptiometry, as a surrogate ...
CVS Caremark will begin offering osteoporosis biosimilars Ospomyv and Stoboclo, as well as generic teriparatide, Bonsity and ...
CVS Health said on Thursday it would swap out Amgen and Eli Lilly's bone disease treatments for lower-cost alternatives in ...
Amgen has denied a request by the FDA to voluntarily withdraw its rare disease drug Tavneos from the market, the company said ...
CVS Health® (NYSE: CVS) today announced new steps to further help customers expand adoption of lower-cost biosimilar medications. Effective April 1, 2026, CVS Caremark will begin offering osteoporosis ...
Denosumab is indicated for treating osteoporosis in postmenopausal women, preventing skeletal-related complications in cancer that has spread to the bone and treating unresectable giant cell tumor of ...
Learn about osteoporosis, its risks, symptoms, and prevention strategies to maintain bone health and prevent fractures.
Investor's Business Daily on MSN
Amgen tops buy zone on positive 2026 outlook amid sharpening obesity focus
Amgen is running a number of studies of its obesity drug, MariTide.
Amgen believes that it can transcend the expected tradeoff between convenience and efficacy, anticipating that its ...
Most women are unaware that their bones reach their maximum strength by about thirty years of age.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results